The central drugs regulator DCGI will soon come out with its recommendations on the application filed for the ZyCoV-D COVID-19 vaccine, according to Dr VK Paul who heads the National Task Force on COVID19 and is a member of the NITI Aayog. ZyCoV-D is a three-dose, DNA plasmid vaccine produced by Ahmedabad based pharma company Zydus Cadila. If approved for use, it would be the first DNA- based COVID-19 vaccine in the world.
Dr Paul said on Friday that the vaccine will be approved for those above the age of 12 years if the scientific data indicates that the vaccine is safe. Zydus has claimed that its vaccine can be administered to children in the age group of 12-18 years. On vaccine efficacy, the company has said that ZyCoV-D provides 66.6% efficacy against symptomatic Covid-19 cases and 100% protection against mild cases of COVID-19.
Currently, four COVID-19 vaccines have been approved in India – Covishield, Covaxin, Sputnik V and Moderna. If ZyCoV-D receives a nod from the DCGI, it would be the country’s second indigenously developed vaccine.
Zydus Cadila has further informed that it has also examined the possibility of using 2 doses and immunogenicity results it found were close to that observed with three doses. On new mutations of the virus like the Delta variant, the company said that its vaccine trial was carried out during the second wave of COVID-19 infections in India when Delta was the dominant variant in the country.
The newly appointed health minister of the country, Mansukh Mandviya, had recently made a visit to the pharma company’s manufacturing plant.
We were honoured to welcome Shri @mansukhmandviya , Hon'ble Minister of State (Independent Charge) for Ministry of Ports,Shipping and Waterways and Minister of State for Chemical & Fertilizers, Government of India, at the Zydus Vaccine Technology Excellence Centre, Ahmedabad. pic.twitter.com/ew2DDYC6An
— Zydus Cadila (@ZydusUniverse) July 4, 2021